

### 16.2.3 Listing of Subjects Excluded From the Safety Population – All Subjects 12 Through 15 Years of Age

| Vaccine Group<br>(as Randomized) | Subject                | Reason for Exclusion                   |
|----------------------------------|------------------------|--|
| BNT162b2 (30 µg)                 | C4591001 1057 10571413 | Subject did not receive study vaccine. |
|                                  | C4591001 1091 10911451 | Subject did not receive study vaccine. |
|                                  | C4591001 1140 11401346 | Subject did not receive study vaccine. |
| Placebo                          | C4591001 1077 10771293 | Subject did not receive study vaccine. |

PFIZER CONFIDENTIAL SDTM Creation: 30SEP2021 (11:35) Source Data: adsl Table Generation: 03NOV2021 (13:12)  
(Data Cutoff Date: 02SEP2021, Database Snapshot Date: 27SEP2021) Output File: ./nda2\_unblinded/C4591001\_S\_Peds/adsl\_l001\_exc\_saf1\_ped6

**16.2.3.1 Listing of Subjects Excluded From All-Available and Evaluable Efficacy Population – Subjects 12 Through 15  
Years of Age – Blinded Placebo-Controlled Follow-up Period**

| <b>Vaccine Group<br/>(as<br/>Randomized)</b> | <b>Age<br/>Group<br/>(Years)</b> | <b>Subject</b>         | <b>Population</b>  | <b>Reason for Exclusion</b>   |
|--|----------------------------------|------------------------|--|---|
| BNT162b2 (30<br>µg)                          | 12-15                            | C4591001 1006 10061272 | Dose 2 all-available<br>efficacy<br>Evaluable efficacy (7<br>days)   | Did not receive 2 vaccinations.<br><br>Randomized but did not meet all eligibility criteria; did not<br>receive all vaccinations as randomized or did not receive Dose 2<br>within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1007 10071409 | Dose 2 all-available<br>efficacy<br>Evaluable efficacy (7<br>days)   | Did not receive 2 vaccinations.<br><br>Did not receive all vaccinations as randomized or did not<br>receive Dose 2 within the predefined window (19-42 days after<br>Dose 1).   |
|  |                                  | C4591001 1007 10071622 | Dose 2 all-available<br>efficacy<br>Evaluable efficacy (7<br>days)   | Did not receive 2 vaccinations.<br><br>Did not receive all vaccinations as randomized or did not<br>receive Dose 2 within the predefined window (19-42 days after<br>Dose 1).   |
|  |                                  | C4591001 1007 10071642 | Dose 2 all-available<br>efficacy<br>Evaluable efficacy (7<br>days)   | Did not receive 2 vaccinations.<br><br>Did not receive all vaccinations as randomized or did not<br>receive Dose 2 within the predefined window (19-42 days after<br>Dose 1).   |
|  |                                  | C4591001 1044 10441359 | Evaluable efficacy (7<br>days)                                       | Did not receive all vaccinations as randomized or did not<br>receive Dose 2 within the predefined window (19-42 days after<br>Dose 1).  |
|  |                                  | C4591001 1057 10571396 | Evaluable efficacy (7<br>days)                                       | Did not receive all vaccinations as randomized or did not<br>receive Dose 2 within the predefined window (19-42 days after<br>Dose 1).  |
|  |                                  | C4591001 1057 10571413 | Dose 1 all-available<br>efficacy<br>Dose 2 all-available<br>efficacy | Did not receive at least 1 vaccination.<br><br>Did not receive 2 vaccinations.  |

090177e1988b7713\Final\Final On: 09-Nov-2021 04:12 (GMT)

**16.2.3.1 Listing of Subjects Excluded From All-Available and Evaluable Efficacy Population – Subjects 12 Through 15  
Years of Age – Blinded Placebo-Controlled Follow-up Period**

| <b>Vaccine Group<br/>(as<br/>Randomized)</b> | <b>Age<br/>Group<br/>(Years)</b> | <b>Subject</b>         | <b>Population</b>             | <b>Reason for Exclusion</b>  |
|--|----------------------------------|------------------------|-------------------------------|--|
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1066 10661407 | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1091 10911414 | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1091 10911451 | Dose 1 all-available efficacy | Did not receive at least 1 vaccination.  |
|  |                                  |                        | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1139 11391261 | Dose 2 all-available efficacy | Unblinded prior to 7 days post Dose 2.   |
|  |                                  |                        | Evaluable efficacy (7 days)   | Unblinded prior to 7 days post Dose 2.   |
|  |                                  | C4591001 1140 11401346 | Dose 1 all-available efficacy | Did not receive at least 1 vaccination.  |
|  |                                  |                        | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |

090177e1988b7713\Final\Final On: 09-Nov-2021 04:12 (GMT)

**16.2.3.1 Listing of Subjects Excluded From All-Available and Evaluable Efficacy Population – Subjects 12 Through 15  
Years of Age – Blinded Placebo-Controlled Follow-up Period**

| <b>Vaccine Group<br/>(as<br/>Randomized)</b> | <b>Age<br/>Group<br/>(Years)</b> | <b>Subject</b>   | <b>Population</b>             | <b>Reason for Exclusion</b>  |
|--|----------------------------------|--|-------------------------------|--|
| Placebo                                      | 12-15                            | C4591001 1142 11421363   | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1).   |
|  |                                  | C4591001 1147 11471327   | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |  | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1).   |
|  |                                  | C4591001 1152 11521641   | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |  | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1).   |
|  |                                  | C4591001 1006 10061219   | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1).   |
|  |                                  | C4591001 1007 10071415   | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1); had other important protocol deviations on or prior to 7 days after Dose 2. |
|  |                                  | C4591001 1007 10071593   | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  | Evaluable efficacy (7 days)      | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |                               |  |
|  |                                  | C4591001 1008 10081871   | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |  | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1).   |

090177e1988b7713\Final\Final On: 09-Nov-2021 04:12 (GMT)

**16.2.3.1 Listing of Subjects Excluded From All-Available and Evaluable Efficacy Population – Subjects 12 Through 15  
Years of Age – Blinded Placebo-Controlled Follow-up Period**

| <b>Vaccine Group<br/>(as<br/>Randomized)</b> | <b>Age<br/>Group<br/>(Years)</b> | <b>Subject</b>         | <b>Population</b>  | <b>Reason for Exclusion</b>   |
|--|----------------------------------|------------------------|--|---|
|  |                                  | C4591001 1008 10081884 | Dose 2 all-available efficacy<br>Evaluable efficacy (7 days) | Did not receive 2 vaccinations.<br>Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1009 10091229 | Dose 2 all-available efficacy<br>Evaluable efficacy (7 days) | Did not receive 2 vaccinations.<br>Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1009 10091320 | Evaluable efficacy (7 days)                                  | Randomized but did not meet all eligibility criteria; had other important protocol deviations on or prior to 7 days after Dose 2.                                   |
|  |                                  | C4591001 1009 10091338 | Dose 2 all-available efficacy<br>Evaluable efficacy (7 days) | Did not receive 2 vaccinations.<br>Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1009 10091363 | Dose 2 all-available efficacy<br>Evaluable efficacy (7 days) | Did not receive 2 vaccinations.<br>Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1009 10091366 | Dose 2 all-available efficacy<br>Evaluable efficacy (7 days) | Did not receive 2 vaccinations.<br>Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1016 10161316 | Dose 2 all-available efficacy                                | Did not receive 2 vaccinations.   |

090177e1988b7713\Final\Final On: 09-Nov-2021 04:12 (GMT)

**16.2.3.1 Listing of Subjects Excluded From All-Available and Evaluable Efficacy Population – Subjects 12 Through 15  
Years of Age – Blinded Placebo-Controlled Follow-up Period**

| <b>Vaccine Group<br/>(as<br/>Randomized)</b> | <b>Age<br/>Group<br/>(Years)</b> | <b>Subject</b>         | <b>Population</b>             | <b>Reason for Exclusion</b>  |
|--|----------------------------------|------------------------|-------------------------------|--|
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1016 10161379 | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1044 10441360 | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1077 10771293 | Dose 1 all-available efficacy | Did not receive at least 1 vaccination.  |
|  |                                  |                        | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1123 11231501 | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1126 11261254 | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1126 11261287 | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |

090177e1988b7713\Final\Final On: 09-Nov-2021 04:12 (GMT)

**16.2.3.1 Listing of Subjects Excluded From All-Available and Evaluable Efficacy Population – Subjects 12 Through 15  
Years of Age – Blinded Placebo-Controlled Follow-up Period**

| <b>Vaccine Group<br/>(as<br/>Randomized)</b> | <b>Age<br/>Group<br/>(Years)</b> | <b>Subject</b>         | <b>Population</b>             | <b>Reason for Exclusion</b>  |
|--|----------------------------------|------------------------|-------------------------------|--|
|  |                                  | C4591001 1131 11311292 | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1147 11471280 | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |
|  |                                  | C4591001 1156 11561359 | Evaluable efficacy (7 days)   | Had other important protocol deviations on or prior to 7 days after Dose 2.  |
|  |                                  | C4591001 1270 12701237 | Dose 2 all-available efficacy | Did not receive 2 vaccinations.  |
|  |                                  |                        | Evaluable efficacy (7 days)   | Did not receive all vaccinations as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1). |

PFIZER CONFIDENTIAL SDTM Creation: 30SEP2021 (11:35) Source Data: adsl Table Generation: 03NOV2021 (11:35)  
(Data Cutoff Date: 02SEP2021, Database Snapshot Date: 27SEP2021) Output File: ./nda2\_unblinded/C4591001 S Peds/adsl l001 excl peds eff pop

090177e1988b7713\Final\Final On: 09-Nov-2021 04:12 (GMT)